Oramed Pharmaceuticals Inc.
Company Snapshot: Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).
- May 5 2020 Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June
- Apr 7 2020 Oramed Patent in Canada Allowed for Oral Delivery of Proteins
- Apr 1 2020 Oramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19
- Mar 19 2020 Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA